Non-Hodgkin's B-cell Lymphoma Clinical Trial
Official title:
A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in Relapsed or Refractory NHL Subjects
The trial is a single arm, single-center, non-randomized phase I clinical trial which is designed to evaluate the safety and efficacy of C-CAR039 in treatment of relapsed or refractory NHL patients
This study plans to enroll 25 patients to assess the safety and efficacy of C-CAR039. Subjects who meet the eligibility criteria will receive a single dose of C-CAR039 injection. The study will include the following sequential phases: Screening, Apheresis and C-CAR039 manufacturing, Bridging (if needed), Baseline, lymphodepletion, C-CAR039 infusion, and Follow-up Visit. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04696432 -
A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma
|
Phase 1 | |
| Terminated |
NCT02361346 -
Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04693676 -
A Study of C-CAR039 Treatment in Subjects With r/r NHL Subjects Non-Hodgkin's Lymphoma
|
Phase 1 | |
| Recruiting |
NCT04655677 -
A Study of EXP039 Treatment in Subjects With r/r NHL Subjects
|
Phase 1 | |
| Suspended |
NCT04148742 -
Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3)
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03000192 -
HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life
|
||
| No longer available |
NCT02715843 -
Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma
|